



**Supplementary Fig. S9:** FDA agents primarily induce G0-G1 and above G2-M arrest in AOCs18.5 clones

Cell cycle profiles of AOCs18.5 fusion-negative (Clone D, Clone E), fusion-positive (Clone 9, Clone 18B) and 50:50 mixed (Clone D: Clone 9) cellular populations following 72hr treatment with 36 different FDA approved agents (0.05, 0.5 and 5μM). Percentage cells in specific cell cycle phase shown. Data determined through DAPI staining from two replicate wells.